KIRhub 2.0· v2

Cabozantinib

a33e41b4-df5c-5f29-8e97-f66264a3c08b · FDA Approved · targets RET, KDR_VEGFR2

Active in EPN: PFA niche (Supported)Active in EPN: ZFTA-RELA (Inconclusive)

Cabozantinib

MeasuredReference

Cabozantinib targets DDR2, NTRK2, DDR1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

DDR2 NTRK2 DDR1 HIPK4 PTK6

Top hallmarks

tumor promoting inflammation2.9k
evading apoptosis2.4k
proliferation2.4k

Top pathways disrupted

apical junction7.1k
allograft rejection6.8k
pi3k akt mtor signaling6.1k

Resistance landscape — Cabozantinib

MeasuredReference

2 known oncogenic variants exist on Cabozantinib's top targets — see detail for inhibition impact.

DDR2 2 known variants
- DDR2 (N456S)
- DDR2 (T654M)

Open in new tab